Covered recipient · General Payments record
MARK L WARREN
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$65,629.93
188 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,562.50 | 24 |
| Travel and Lodging | $11,977.73 | 46 |
| Consulting Fee | $7,125.00 | 4 |
| Food and Beverage | $4,774.85 | 113 |
| Education | $189.85 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $23,125.09 | 39 |
| Lilly USA, LLC | $19,001.01 | 50 |
| Abbott Laboratories | $10,234.91 | 30 |
| Eli Lilly and Company | $7,743.01 | 14 |
| AstraZeneca Pharmaceuticals LP | $1,496.78 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. | $1,491.50 | 11 |
| Tandem Diabetes Care, Inc. | $1,473.20 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $252.03 | 3 |
| Medtronic, Inc. | $223.43 | 4 |
| Ascendis Pharma Inc | $108.23 | 1 |
| Mannkind Corporation | $104.43 | 2 |
| Corcept Therapeutics | $84.30 | 4 |
| Novo Nordisk Inc | $78.64 | 5 |
| Insulet Corporation | $60.66 | 1 |
| CeQur Corporation | $45.56 | 1 |
| Averitas Pharma Inc. | $27.17 | 1 |
| Amneal Pharmaceuticals LLC | $19.64 | 1 |
| Ascensia Diabetes Care Us Inc. | $17.69 | 1 |
| Dexcom, Inc. | $14.64 | 1 |
| RECORDATI_RARE_DISEASES_INC. | $14.33 | 1 |
| Verity Pharmaceuticals Inc. | $13.68 | 1 |
Page 3 of 4; records 101–150 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARK L WARREN
NPI 1629073010 · CMS profile ID 209984
Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism
GREENVILLE, NC
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1629073010?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARK L WARREN, NPI 1629073010, CMS profile ID 209984. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629073010?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MARK L WARREN, NPI 1629073010, CMS profile ID 209984. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629073010?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MARK L WARREN, NPI 1629073010, CMS profile ID 209984, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 188 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1629073010?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
188 matching records · $65,629.93 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 188.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $132.10 | 06/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135155073 | CMS |
| Lilly USA, LLC | $132.10 | 06/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135155075 | CMS |
| Lilly USA, LLC | $483.28 | 06/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135161679 | CMS |
| Lilly USA, LLC | $220.13 | 06/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135161681 | CMS |
| Amgen Inc. | $140.40 | 05/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736298 | CMS |
| Amgen Inc. | $10.13 | 05/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736334 | CMS |
| Novo Nordisk Inc | $13.55 | 04/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1096596154 | CMS |
| Amgen Inc. | $2,400.00 | 04/24/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736338 | CMS |
| Amgen Inc. | $104.51 | 04/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736336 | CMS |
| Abbott Laboratories | $400.00 | 04/05/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125422703 | CMS |
| Abbott Laboratories | $0.31 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125158092 | CMS |
| Abbott Laboratories | $1.92 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125158094 | CMS |
| Abbott Laboratories | $21.87 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125158096 | CMS |
| Abbott Laboratories | $0.19 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125158098 | CMS |
| Abbott Laboratories | $134.20 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125158100 | CMS |
| Dexcom, Inc. | $14.64 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153320034 | CMS |
| Lilly USA, LLC | $24.12 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135155077 | CMS |
| Abbott Laboratories | $2,100.00 | 03/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1125422701 | CMS |
| Insulet Corporation | $60.66 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116798081 | CMS |
| Corcept Therapeutics | $23.96 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117753634 | CMS |
| Lilly USA, LLC | $9.51 | 03/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135156875 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $46.94 | 03/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086080516 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $173.73 | 03/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086080584 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $548.20 | 03/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086081026 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $95.48 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086130572 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $33.03 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086135089 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $32.00 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086192602 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $33.03 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086192604 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $86.49 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086231202 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $50.00 | 03/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086231204 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $206.50 | 03/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086080582 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $186.10 | 03/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086080768 | CMS |
| Ascensia Diabetes Care Us Inc. | $17.69 | 03/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089089324 | CMS |
| Amgen Inc. | $100.50 | 03/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736280 | CMS |
| Amgen Inc. | $2,400.00 | 03/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736284 | CMS |
| Amgen Inc. | $2,400.00 | 03/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736286 | CMS |
| Amgen Inc. | $400.00 | 03/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736288 | CMS |
| Amgen Inc. | $400.00 | 03/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736290 | CMS |
| Amgen Inc. | $123.28 | 03/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736282 | CMS |
| Amgen Inc. | $125.00 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736294 | CMS |
| Amgen Inc. | $600.00 | 03/03/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736314 | CMS |
| Novo Nordisk Inc | $14.83 | 02/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1097675088 | CMS |
| Amgen Inc. | $4.37 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736316 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $14.33 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139167311 | CMS |
| Amgen Inc. | $2,400.00 | 02/26/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736328 | CMS |
| Amgen Inc. | $400.00 | 02/26/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736330 | CMS |
| Amgen Inc. | $68.34 | 02/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1111736326 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35.00 | 02/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118084944 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $115.00 | 02/24/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118084948 | CMS |
| Lilly USA, LLC | $21.50 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135115263 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $500,365.48 | 199 |
| PY2024 | Recipient | $17,123.42 | 29 |
| PY2024 | Principal investigator | $769,344.58 | 122 |
| PY2023 | Recipient | $1,173.86 | 8 |
| PY2023 | Principal investigator | $453,635.21 | 173 |
| PY2022 | Recipient | $1,754.86 | 8 |
| PY2022 | Principal investigator | $568,061.57 | 200 |
| PY2021 | Principal investigator | $588,948.55 | 2,089 |
| PY2020 | Recipient | $1,190.00 | 3 |
| PY2020 | Principal investigator | $493,531.93 | 476 |
| PY2019 | Recipient | $1,642.00 | 1 |
| PY2019 | Principal investigator | $750,222.66 | 183 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
199 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $5,520.00 | 12/31/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism | No dispute reported | 06/30/2026 | 1202534039 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 12/17/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653446 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,473.10 | 12/10/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220791302 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6,000.00 | 12/03/2025 | Non-covered Recipient Entity Physicians East PA - 1006 WH Smith | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508340 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,598.00 | 12/03/2025 | Non-covered Recipient Entity Physicians East PA - 1006 WH Smith | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508345 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653310 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653312 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653444 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220653458 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 11/20/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220995392 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 11/19/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653314 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 11/19/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653316 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.92 | 11/19/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653318 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16.56 | 11/19/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653320 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,816.10 | 11/13/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220791300 |
| Principal investigator 1 | ABBVIE INC. | $16,861.00 | 11/05/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202521697 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $463.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997446 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $463.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997448 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $463.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997450 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $463.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997452 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $369.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997468 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $369.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997470 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $369.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997472 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $369.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997474 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $263.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997476 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $263.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997478 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $263.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997480 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $263.00 | 11/03/2025 | Non-covered Recipient Entity Physicians East, PA | EAP of Palopegteriparatide in Patients With Hypoparathyroidism | No dispute reported | 06/30/2026 | 1233997482 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653308 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653440 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653442 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220653456 |
| Principal investigator 1 | Novo Nordisk AS | $1,064.25 | 10/29/2025 | Non-covered Recipient Entity PHYSICIANS EAST ENDOCRINOLOGY | NN8640-4515 | No dispute reported | 06/30/2026 | 1213706610 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 10/27/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220653460 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220653462 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,933.00 | 10/16/2025 | Non-covered Recipient Entity Physicians East Pa | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225413942 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,376.20 | 10/10/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220791284 |
| Principal investigator 1 | ABBVIE INC. | $13,505.70 | 10/09/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202514977 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653306 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653434 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653436 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653438 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 10/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220653448 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 10/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220653450 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 10/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220653452 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220653454 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 09/24/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653304 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 09/24/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653432 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/17/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220794429 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/17/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220794431 |
| Principal investigator 1 | ABBVIE INC. | $9,629.10 | 09/04/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202508702 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,890.00 | 09/03/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220791286 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653280 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653282 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653284 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653286 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653396 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653398 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653400 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653402 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653420 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653422 |
| Principal investigator 1 | Novo Nordisk AS | $1,064.25 | 08/22/2025 | Non-covered Recipient Entity PHYSICIANS EAST ENDOCRINOLOGY | NN8640-4515 | No dispute reported | 06/30/2026 | 1213727181 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,061.90 | 08/20/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220791298 |
| Principal investigator 1 | ABBVIE INC. | $14,677.00 | 08/06/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202502512 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653272 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653274 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653276 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653278 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $61.58 | 08/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653412 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653418 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,977.00 | 08/01/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220791282 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,251.00 | 07/31/2025 | Non-covered Recipient Entity Physicians East Pa | A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney disease a | No dispute reported | 06/30/2026 | 1225413356 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 07/28/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653296 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 07/28/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653298 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 07/28/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653300 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.14 | 07/28/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653302 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 07/28/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653424 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $584.00 | 07/28/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653426 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27.84 | 07/28/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653428 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.12 | 07/28/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653430 |
| Principal investigator 1 | Eli Lilly and Company | $1,072.00 | 07/28/2025 | Non-covered Recipient Entity DANBURY CLINICAL RESEARCH LLC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187878639 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $2,608.20 | 07/10/2025 | Non-covered Recipient Entity KMW, Inc | PaTHway TRIAL | No dispute reported | 06/30/2026 | 1233996533 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $1,950.00 | 07/10/2025 | Non-covered Recipient Entity KMW, Inc | PaTHway TRIAL | No dispute reported | 06/30/2026 | 1233996535 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $1,090.80 | 07/10/2025 | Non-covered Recipient Entity KMW, Inc | PaTHway TRIAL | No dispute reported | 06/30/2026 | 1233996537 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $1,060.80 | 07/10/2025 | Non-covered Recipient Entity KMW, Inc | PaTHway TRIAL | No dispute reported | 06/30/2026 | 1233996539 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $1,060.80 | 07/10/2025 | Non-covered Recipient Entity KMW, Inc | PaTHway TRIAL | No dispute reported | 06/30/2026 | 1233996541 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $892.00 | 07/10/2025 | Non-covered Recipient Entity KMW, Inc | PaTHway TRIAL | No dispute reported | 06/30/2026 | 1233996543 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $900.00 | 07/09/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220791296 |
| Principal investigator 1 | ABBVIE INC. | $23,284.30 | 07/02/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202494121 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653288 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653290 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653292 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653294 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653404 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653406 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653408 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653410 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653414 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 07/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653416 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 06/24/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653268 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 06/24/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653270 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 06/24/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653390 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 06/24/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653392 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 06/24/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653394 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,805.80 | 06/12/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220791280 |
| Principal investigator 1 | ABBVIE INC. | $35,578.40 | 06/03/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202488529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653254 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653256 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653258 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653260 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653376 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653378 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653380 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653382 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653384 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $60.00 | 05/12/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220794425 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $60.00 | 05/12/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220794427 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,061.90 | 05/09/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220791294 |
| Principal investigator 1 | ABBVIE INC. | $14,794.00 | 05/07/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202482595 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.89 | 05/06/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220794423 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,622.40 | 05/05/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220791278 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653246 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653248 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653250 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653366 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653368 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653370 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653372 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653374 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,890.80 | 05/01/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220791276 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $900.00 | 05/01/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220791292 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,619.00 | 04/28/2025 | Non-covered Recipient Entity Physicians East Pa | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225403693 |
| Principal investigator 1 | Amgen Inc. | $22,133.00 | 04/24/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM | No dispute reported | 06/30/2026 | 1246646528 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 04/23/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653262 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 04/23/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653264 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.28 | 04/23/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653266 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 04/23/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653386 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 04/23/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653388 |
| Principal investigator 1 | ABBVIE INC. | $4,890.60 | 04/03/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202471525 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $2,678.40 | 04/03/2025 | Non-covered Recipient Entity KMW, Inc | PaTHway TRIAL | No dispute reported | 06/30/2026 | 1233995285 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653240 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653242 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653244 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653356 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653358 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653360 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653362 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653364 |
| Principal investigator 1 | Novo Nordisk AS | $22,865.48 | 03/31/2025 | Non-covered Recipient Entity PHYSICIANS EAST, PA | EX9924-4473 | No dispute reported | 06/30/2026 | 1213774291 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,227.00 | 03/27/2025 | Non-covered Recipient Entity Physicians East Pa | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225404684 |
| Principal investigator 1 | Ascendis Pharma Endocrinology Inc | $15,902.88 | 03/26/2025 | Non-covered Recipient Entity KMW, Inc | PaTHway TRIAL | No dispute reported | 06/30/2026 | 1233995239 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,099.70 | 03/24/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220791290 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,318.70 | 03/13/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220791274 |
| Principal investigator 1 | Eli Lilly and Company | $10,217.00 | 03/11/2025 | Non-covered Recipient Entity PHYSICIANS EAST | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187889498 |
| Principal investigator 1 | ABBVIE INC. | $17,685.20 | 03/07/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202459473 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,579.00 | 03/06/2025 | Non-covered Recipient Entity Physicians East Pa | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225403239 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653230 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653232 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653234 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653236 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653340 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653342 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653344 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653346 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653348 |
| Principal investigator 1 | Amgen Inc. | $7,370.41 | 02/25/2025 | Non-covered Recipient Entity PHYSICIANS EAST | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246646532 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,801.75 | 02/21/2025 | Non-covered Recipient Entity PHYSICIANS EAST URGENT CARE CENTER | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria | No dispute reported | 06/30/2026 | 1185538176 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,647.40 | 02/21/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220791272 |
| Principal investigator 1 | ABBVIE INC. | $7,373.60 | 02/06/2025 | Non-covered Recipient Entity PHYSICIANS EAST PA | M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants | No dispute reported | 06/30/2026 | 1202446883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653222 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653224 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653226 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653228 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653330 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653332 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653334 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653336 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653338 |
| Principal investigator 1 | Amgen Inc. | $42,888.34 | 01/30/2025 | Non-covered Recipient Entity PHYSICIANS EAST | A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM | No dispute reported | 06/30/2026 | 1246646536 |
| Principal investigator 1 | Medtronic, Inc. | $59.00 | 01/30/2025 | Non-covered Recipient Entity Kmw Inc | CIP341 IMPACT2 | No dispute reported | 06/30/2026 | 1192322783 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,209.00 | 01/28/2025 | Non-covered Recipient Entity Physicians East Pa | BAY 948862, A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3study to investigate the efficacy and safety of finerenone versus placebo, in addition to standard of care, in participants with chronic kidney | No dispute reported | 06/30/2026 | 1225403085 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 01/27/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653350 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 01/27/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653352 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,329.00 | 01/22/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220791270 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $900.00 | 01/17/2025 | Non-covered Recipient Entity Physicians East PA MRI | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220791288 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $39,699.37 | 01/16/2025 | Non-covered Recipient Entity KMW INCORPORATED | Eneboparatide - Calypso study which is a pivotal phase 3 study investigational therapeutic peptide with a novel mechanism of action for hypoparathyroidism | No dispute reported | 06/30/2026 | 1185538178 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,665.87 | 01/08/2025 | Non-covered Recipient Entity PHYSICIANS EAST URGENT CARE CENTER | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185538174 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653214 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653216 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653218 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | No dispute reported | 06/30/2026 | 1220653220 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653322 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653324 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653326 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653328 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Physicians East Properties LLC | A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes | No dispute reported | 06/30/2026 | 1220653354 |